Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol

S Almond, O O'Donnell


To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia. The analysis is based on a simulation model with parameter values taken mainly from clinical trial data in patients with schizophrenia, and was conducted within a UK context. The 3 therapies are approximately cost neutral over a 5-year period (olanzapine 35,701 Pounds, risperidone 36,590 Pounds and haloperidol 36,653 Pounds). There is evidence of greater efficacy with the atypical drugs [average percentage of 5 years with Brief Psychiatric Rating Scale (BPRS) scores < 18: olanzapine 63.6%, risperidone 63.0% and haloperidol 52.2%]. The cost and efficacy differences between the 2 atypical drugs are too small to rank them in terms of cost effectiveness. Extensive sensitivity analysis does not change any of the main conclusions. Given evidence of efficacy gains to the atypical drugs, these represent cost-effective treatment options. Prospective data from nontrial treatment settings would help substantiate the model findings.


❮ Previous
Next ❯


Oct 31, 2002·Human Psychopharmacology·Stephen CurranDavid Silkstone
Mar 11, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Karina HansenMondher Toumi
Aug 10, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Stephen M BeardEckart Rüther
Sep 18, 2001·Current Psychiatry Reports·P F BuckleyB Singer
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Simon SurguladzeMichael J Travis
Dec 31, 2002·Archives of Medical Research·Cynthia S PalmerDennis A Revicki
Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
Jan 22, 2005·The Australian and New Zealand Journal of Psychiatry·Anne MagnusTheo Vos
Nov 14, 2007·International Journal of Clinical Practice·M ObradovicM Kos
Jul 26, 2012·Health Economics Review·Antonio J García-RuizMiguel A Casado
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
Jul 5, 2003·Current Medical Research and Opinion·Stephen D MartinB T Saleh
Sep 23, 2008·The Kaohsiung Journal of Medical Sciences·Shu-Jen Shiau, Chung-Hey Chen
Apr 9, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jihyung HongJacqueline Brown
Mar 18, 2006·Acta Psychiatrica Scandinavica. Supplementum·L KopalaR Balshaw
Dec 1, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Anita Patel
Jul 1, 2003·Expert Review of Neurotherapeutics·Pierre Chue
Jul 21, 2011·Nordic Journal of Psychiatry·Eva LindströmChristophe Sapin
Jan 9, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Linda M DaviesUNKNOWN CUTLASS Team
Mar 25, 2006·Thérapie·András KlebovichRomána Zelkó
Jul 23, 2003·The Journal of International Medical Research·A MortimerD Meddis
Feb 26, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Birgitta von SchéeleAnita Patel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here